Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Dive Brief:

• Jazz Pharmaceuticals has agreed to buy a San Diego-based biotechnology company developing treatments for genetic epilepsies, through a deal that could be worth just over $1.3 billion.
• Terms hold that privately held Actio Biosciences will receive $820 million up front and be eligible for $500 million in additional payments if its research programs hit certain regulatory and sales milestones. The company’s most advanced drug is being tested against a rare form of epilepsy caused by mutations in a gene known as KCNT1.
• The companies expect to close their deal sometime in the final three months of the year. Concurrent with the closing, Actio will spin out a new private entity funded by existing investors and headlined by one of its other programs, an ion channel inhibitor in early-stage testing for a form of “Charcot-Marie-Tooth,” an uncommon neurological disease. Jazz said it will hold a minority stake in the spinout — an investment that, by focusing on rare diseases, “represents a strong strategic fit” for its long-term strategy.

Dive Insight:

Actio adds to a significant upswing in buyouts of private, venture capital-backed biotechs. A report from HSBC Innovation Banking tallied 19 such acquisitions in the first half of 2026, eclipsing the annual totals seen in each of the last five years. And over that six-month period, the median deal value reached $950 million — roughly three times higher than what was seen in the early 2020s.

By buying Actio, Jazz would further expand the research pipeline for one of its two main therapeutic areas: neuroscience. The company’s top sellers include the sleep medication Xywav and Epidiolex, a CBD-based treatment for a couple kinds of rare, severe childhood epilepsies. Jazz just recorded its largest ever total quarterly revenue of $1.2 billion, a 16% year-over-year increase.

The acquisition is “highly strategic,” building on the success of the Epidiolex franchise and “deepening our leadership in rare and severe epilepsies," Jazz’s CEO Renee Gala said in a statement.

Actio’s lead asset, codenamed ABS-1230, is a potentially first-of-its-kind medicine for KCNT1-related epilepsy — a disease that has no approved treatments and, according to estimates cited by Jazz, affects around 2,500 people in the U.S. In more severe cases, patients can experience dozens, sometimes hundreds of seizure episodes a day. These seizures are often resistant to medications and can cause severe developmental delays and an early death.

ABS-1230 is designed to block the overly active potassium ion channels that make the brain’s circuitry hyper-excited and prone to seizures. Actio and Jazz said the drug recently produced “meaningful seizure reductions” in a so-called proof-of-concept trial. It’s now being evaluated in a roughly 55-participant study that could serve as the foundation for an approval application in the U.S.

Actio said there are also opportunities to test the drug in more prevalent genetic epilepsies.

Jazz’s development experience and commercial scale should “ensure ABS-1230 is brought to patients as quickly and efficiently as possible," said David Goldstein, Actio’s CEO, in that Monday statement.

Jazz intends to fund the deal with cash on hand and by drawing on existing financing facilities. The company reported $2.2 billion in cash, cash equivalents and investments as of June 30. The outstanding principal balance of its long-term debt was $4.4 billion by that date. It had also undrawn borrowing capacity under a revolving credit facility of $885 million.

Joseph Thome, a TD Cowen analyst who covers Jazz, wrote in a note to clients that the acquisition adds "meaningful pipeline optionality," though his team wants to see detailed patient-level data, a timeline for results from that key study, as well as clarity on the regulatory package before "assigning material value" to Actio's drug.